Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2381-2390

  Rider, Lisa G ^a   Wu, Lan ^a   Mamyrova, Gulnara ^a,c   Targoff, Ira N ^b   Miller, Frederick W ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Environmental factor; Infection; Juvenile myositis; Medication; Myositis autoantibody; Phenotype

Indexed keywords

AUTOANTIBODY;

ANTIGEN RECOGNITION; ARTICLE; CHILD; DISEASE COURSE; DRUG EXPOSURE; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; IMMUNIZATION; INFECTION; JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHY; LIFE EVENT; LIFE STRESS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOSITIS; PHENOTYPE; PRIORITY JOURNAL; SUN EXPOSURE;

AGE OF ONSET; AUTOANTIBODIES; CHILD, PRESCHOOL; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MYOSITIS; PHENOTYPE; RISK FACTORS; TIME FACTORS;

EID: 78549235814     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq277     Document Type: Article

References (44)

1. Cooper GS, Miller FW, Germolec DR. Occupational exposures and autoimmune diseases. Int Immunopharmacol 2002;2:303-13.
2. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12.
3. Rider LG. The heterogeneity of juvenile myositis. Autoimmun Rev 2007;6:241-7.
4. Gunawardena H, Wedderburn LR, North J et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008;47:324-8.
5. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
6. Pachman LM, Abbott K, Sinacore JM et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006;148:247-53.
7. Christen-Zaech S, Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent association of nailfold capillaroscopy changes and skin involvement over thirty-six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis Rheum 2008;58:571-6.
8. Huber AM, Lang B, LeBlanc CM et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
9. Gourley M, Miller FW. Mechanisms of disease: environ-mental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol 2007;3:172-80.
10. Mamyrova G, O'Hanlon TP, Monroe JB et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006;54: 3979-87.
11. O'Hanlon TP, Rider LG, Mamyrova G et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006;54:3670-81.
12. Pachman LM, Liotta-Davis MR, Hong DK et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:2368-77.
13. Mamyrova G, O'Hanlon TP, Sillers L et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008;58: 3941-50.
14. Chinoy H, Platt H, Lamb JA et al. The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 2008;58:3247-54.
15. O'Hanlon TP, Rider LG, Schiffenbauer A et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008;58:3239-46.
16. Pachman LM, Lipton R, Ramsey-Goldman R et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005;53:166-72.
17. Manlhiot C, Liang L, Tran D, Bitnun A, Tyrrell PN, Feldman BM. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology 2008;47:526-9.
18. Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. N Engl J Med 1975;292:344-7,3403-7.
19. Pachman LM, Hayford JR, Hochberg MC et al. New-onset juvenile dermatomyositis: comparisons with a healthy cohort and chidren with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1526-33.
20. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 1986;29:1365-70.
21. Compas BE, Davis GE, Forsythe CJ, Wagner BM. Assessment of major and daily stressful events during adolescence: the Adolescent Perceived Events Scale. J Consult Clin Psychol 1987;55:534-41.
22. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996;39:1507-18.
23. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990; 144:1737-43.
24. Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest 1993;91:2556-64.
25. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist 1979;6:65-70.
26. Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitizing diseases induced by exogenous agents. J Am Acad Dermatol 1995;33:551-73.
27. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002;25:345-72.
28. Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin 2005; 23:397-428.
29. Guis S, Mattei JP, Liote F. Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 2003;17: 877-907.
30. Wald JJ. The effects of toxins on muscle. Neurol Clin 2000;18:695-718.
31. Love LA, Miller FW. Noninfectious environmental agents associated with myopathies. Curr Opin Rheumatol 1993;5:712-8.
32. Lambert SB, Allen KM, Druce JD et al. Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy preschool-aged children using parent-collected specimens. Pediatrics 2007;120:e929-37.
33. Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol 2008;59:872-80.
34. Dourmishev LA, Dourmishev AL. Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations. Expert Opin Drug Saf 2008;7:421-33.
35. Lyon MG, Bloch DA, Hollak B, Fries JF. Predisposing factors in polymyositis-dermatomyositis: results of a nationwide survey. J Rheumatol 1989;16:1218-24.
36. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003;48:2285-93.
37. Miller FW. Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In: Koopman W, Moreland L, eds. Arthritis and allied conditions: a textbook of rheumatology. Philadelphia: Lippincott Williams & Wilkins, 2005:1593-620.
38. Miller FW. Noninfectious environmental agents and autoimmunity. In: Rose NR, Mackay IR, eds. The autoimmune diseases. Boston: Elsevier, 2006:297-308.
39. Coenen MJ, Gregersen PK. Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun 2009;10: 101-11.
40. Belpomme D, Irigaray P, Hardell L et al. The multitude and diversity of environmental carcinogens. Environ Res 2007;105:414-29.
41. Sell S. Mouse models to study the interaction of risk factors for human liver cancer. Cancer Res 2003;63:7553-62.
42. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-308.
43. Miller FW, Hess EV, Clauw DJ et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000;43:243-9.
44. Mamyrova G, Rider LG, Haagenson L, Wong S, Brown KE. Parvovirus B19 and onset of juvenile dermatomyositis. JAMA 2005;294:2170-1.